Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Phase-Appropriate Bioanalytics for Preclinical Therapeutic Development

PHASE-APPROPRIATE BIOANALYTICAL SUPPORT FOR GXP AND NON-GXP PROGRAMS

Phase-Appropriate Bioanalytics for Preclinical Therapeutic Development

CELL & GENE | RNA | BIOLOGICS

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Proven Intelligence in Phase-Appropriate Bioanalytics.

Executive Summary

A phase-appropriate bioanalytical strategy is fundamental to navigating the development pathway for next-generation therapeutics. This approach aligns the rigor of in vivo bioanalytical testing with the specific stage of a program, utilizing non-GxP studies for early discovery and mechanism of action, and transitioning to GxP-compliant assays for formal IND-enabling toxicology studies. This ensures that resource allocation is efficient, data is fit-for-purpose, and regulatory submissions are built on a solid foundation of scientifically sound evidence. Franklin Biolabs provides this tailored support across our >100,000 sq ft facility, leveraging a scientific team whose track record includes a 100% successful IND rate since 2019, established prior to our formal launch in 2024.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Frequently Asked Questions

What is the primary distinction between GxP and non-GxP bioanalytical support for in vivo programs?

The primary distinction lies in the regulatory intent and level of documentation. Non-GxP bioanalytical support is for research, discovery, and establishing proof-of-concept, prioritizing scientific flexibility. GxP-compliant support is for formal IND-enabling toxicology studies, requiring rigorous documentation, validation, and adherence to international guidelines (e.g., ICH) to ensure data integrity for regulatory review.

How do you develop bioanalytical assays for novel RNA therapeutics or gene editing platforms?

Assay development for novel modalities is a science-driven process that begins with a deep understanding of the platform’s mechanism of action. We design custom assays to measure payload delivery, target engagement, protein expression, and potential immunogenicity, ensuring the bioanalytical endpoints are directly relevant to the therapeutic hypothesis and potential safety profile.

At what point should a program transition from non-GLP discovery to GLP conditions for its bioanalytical assays?

The transition occurs when a lead candidate is selected and the program focus shifts to generating the formal safety and toxicology data required for an IND submission. Early non-GLP assays often inform the design and qualification of the final GxP assays used in pivotal IND-enabling toxicology studies, ensuring continuity and building a comprehensive data package.

Next-generation therapeutics require a tailored bioanalytical plan. The scientific questions being asked at the discovery stage are fundamentally different from those required for a formal regulatory submission. A phase-appropriate strategy aligns analytical rigor with program maturity, conserving resources while maximizing the value of the data generated from in vivo models.

This tailored approach is a core component of our work, including our collaboration with Moderna, and is designed to support sponsors in achieving their 18-24 month IND timelines.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Delineating Non-GxP and GxP Objectives

The decision to operate under GxP or non-GxP conditions is driven by the intended use of the data. Early-stage research benefits from the flexibility of non-GxP work, while late-stage preclinical programs demand the structured environment of GxP compliance.

Attribute Non-GxP Bioanalytical Support GxP Bioanalytical Support
Primary Goal Discovery, lead optimization, mechanism of action IND-enabling safety & toxicology
Application Proof-of-concept, dose-range finding Formal regulatory submissions (IND, IMPD)
Assay Status Qualified or fit-for-purpose Fully validated per regulatory guidelines
Documentation Lab notebooks, research reports Comprehensive, auditable records
Flexibility High; methods can be adapted rapidly Low; strict adherence to validated SOPs

Translational Application Across Modalities

This dual-track approach is valuable for de-risking complex programs. For an AAV-delivered gene editing platform, initial non-GxP studies in nonhuman primate models might focus on quantifying guide RNA and editor expression in target tissues to confirm delivery. The translational impact of this early work is significant, as it provides the foundational durability data necessary to justify investment in a formal GxP study (PMID: 33609733).

For a non-viral LNP-based therapy, bioanalytical assays in a Phase 2b context must demonstrate consistent biological activity and measure key pharmacodynamic biomarkers over time. The methods used to generate this data build upon earlier, non-GxP discovery work to provide confidence in the therapeutic’s mechanism of action for later-stage development (PMID: 26149841).

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Commitment to In Vivo Program Integrity

All in vivo work, whether for GxP or non-GxP bioanalytical sample generation, is conducted with an unwavering commitment to animal welfare. Our programs adhere to the 3Rs principle (Replacement, Reduction, and Refinement). This focus on high-quality animal care and ethical conduct ensures the integrity of the biological samples collected for downstream analysis.

Our scientific team provides the expert bioanalytical support needed to interpret complex datasets and build a cohesive narrative for regulatory agencies. This is a key part of the comprehensive support offered through our Bioanalytical Services.

Visualizing the Bioanalytical Pathway: Discovery vs. Regulatory

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities